Cochrane Abstracts
Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Dipeptidyl Peptidase‐4 Inhibitors, Glucagon‐like Peptide 1 Receptor Agonists and Sodium‐glucose Co‐transporter‐2 Inhibitors for People With Cardiovascular Disease: a Network Meta‐analysis." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/433293/all/Dipeptidyl_peptidase‐4_inhibitors__glucagon‐like_peptide_1_receptor_agonists_and_sodium‐glucose_co‐transporter‐2_inhibitors_for_people_with_cardiovascular_disease:_a_network_meta‐analysis.
Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433293/all/Dipeptidyl_peptidase‐4_inhibitors__glucagon‐like_peptide_1_receptor_agonists_and_sodium‐glucose_co‐transporter‐2_inhibitors_for_people_with_cardiovascular_disease:_a_network_meta‐analysis. Accessed December 7, 2024.
Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/433293/all/Dipeptidyl_peptidase‐4_inhibitors__glucagon‐like_peptide_1_receptor_agonists_and_sodium‐glucose_co‐transporter‐2_inhibitors_for_people_with_cardiovascular_disease:_a_network_meta‐analysis
Dipeptidyl Peptidase‐4 Inhibitors, Glucagon‐like Peptide 1 Receptor Agonists and Sodium‐glucose Co‐transporter‐2 Inhibitors for People With Cardiovascular Disease: a Network Meta‐analysis [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 07]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/433293/all/Dipeptidyl_peptidase‐4_inhibitors__glucagon‐like_peptide_1_receptor_agonists_and_sodium‐glucose_co‐transporter‐2_inhibitors_for_people_with_cardiovascular_disease:_a_network_meta‐analysis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis
ID - 433293
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/433293/all/Dipeptidyl_peptidase‐4_inhibitors__glucagon‐like_peptide_1_receptor_agonists_and_sodium‐glucose_co‐transporter‐2_inhibitors_for_people_with_cardiovascular_disease:_a_network_meta‐analysis
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
